IL1B and inflammatory bowel disease: However, BSB was administered after IBD induction, and it significantly (p < 0.001, n = 6) reduced IL-1β levels from 273.36 ± 23.63 (no BSB, n = 6) to 110.70 ± 14.07 (BSB, n = 6) pg/mg of protein and from 205.36 ± 44.32 (no BSB, n = 6) to 48.99 ± 4.29 (BSB, n = 6) pg/mg of protein on days 2 and 4 days of IBD, respectively.